Asgard Therapeutics

Asgard Therapeutics is a biotech company developing in vivo direct cell reprogramming for cancer immunotherapy. Their lead program, AT-108, reprograms tumor cells into antigen-presenting dendritic cells, triggering a personalized anti-tumor immune response. This approach offers a potential breakthrough in cancer treatment by overcoming challenges faced by traditional cell therapies.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: €30M

Date: 14-Mar-2024

Investors: RV Invest, Johnson & Johnson Innovation – JJDC, Inc., Novo Holdings, Boehringer Ingelheim Venture Fund, Industrifonden

Markets: Biotechnology, Immunotherapy, Oncology, Gene Therapy

HQ: Lund, Skåne, Sweden

Founded: 2018

Website: https://www.asgardthx.com/

LinkedIn: https://www.linkedin.com/company/asgardthx/

Twitter: https://twitter.com/AsgardThx

Instagram: